Carazolol (CAS 57775-29-8)

The exocyst complex is a multi-protein complex essential for targeting and tethering vesicles to specific sites on the plasma membrane, where they can then fuse and release their contents. It plays a critical role in exocytosis, which is the process by which cells transport molecules out of the cell in membrane-bound vesicles. EXOC proteins, which are components of the exocyst complex, interact with small GTPases like Rho and Rab, which act as molecular switches to regulate vesicle docking. These interactions are crucial for the spatial and temporal specificity of vesicle fusion, ensuring that cargo is delivered to the right place at the right time within the cell. The signaling pathways involving EXOC proteins are vital for many cellular processes, including morphogenesis, cell growth, and neurotransmitter release in neurons. Exocyst complex component (EXOC) inhibitors pertain to a class of chemical agents designed to selectively disrupt the normal functioning of the exocyst complex, a pivotal assembly of proteins that are integral to the process of exocytosis in eukaryotic cells. This complex, composed of multiple protein subunits such as Sec3, Sec5, Sec6, Sec8, Sec10, Sec15, Exo70, and Exo84, is implicated in the final stages of cell vesicle trafficking where it facilitates the tethering of transport vesicles to the plasma membrane. Inhibitors targeting the exocyst complex function by interfering with the complex′s ability to assemble or by obstructing its interaction with other cellular machinery necessary for the vesicle fusion process.